← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Delcath Systems, Inc. (DCTH) 10-Year Financial Performance & Capital Metrics

DCTH • • Industrial / General
HealthcareMedical DevicesOncology & Cancer Treatment DevicesRadiation Therapy Systems
AboutDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Show more
  • Revenue $37M +1701.7%
  • EBITDA -$12M +67.8%
  • Net Income -$26M +44.7%
  • EPS (Diluted) -0.93 +68.5%
  • Gross Margin 83.37% +20.4%
  • EBITDA Margin -32.74% +98.2%
  • Operating Margin -33.36% +98.2%
  • Net Margin -70.92% +96.9%
  • ROE -62.44% +93.5%
  • ROIC -36.72% +90.0%
  • Debt/Equity 0.02 -97.7%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Strong 5Y sales CAGR of 88.1%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 75.7% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y42.61%
5Y88.1%
3Y118.74%
TTM251.54%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM103.51%

EPS CAGR

10Y-
5Y-
3Y-
TTM100.64%

ROCE

10Y Avg-2258.23%
5Y Avg-166.74%
3Y Avg-184.07%
Latest-26.8%

Peer Comparison

Radiation Therapy Systems
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
SRTSSensus Healthcare, Inc.81.47M4.9612.1071.31%-8.44%-5.87%0.01
CATXPerspective Therapeutics, Inc.184.36M2.48-2.02-100%-197.29%-42.77%0.01
TLSITriSalus Life Sciences, Inc.307.28M6.15-4.9258.99%-98.45%
PROFProfound Medical Corp.302.68M8.34-7.7941.23%-272.77%-130.59%0.08
DCTHDelcath Systems, Inc.354.29M10.21-11.0317.02%1.5%1.04%0.02
PTHLPheton Holdings Ltd Class A Ordinary Shares8.46M0.90-17.38-28.7%-91.16%-13.91%0.04
ARAYAccuray Incorporated98.61M0.87-56.132.68%-4.28%-31.22%2.17

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+1.75M1.99M2.71M3.41M1.58M1.65M3.56M2.72M2.06M37.2M
Revenue Growth %0.63%0.14%0.36%0.25%-0.54%0.04%1.16%-0.24%-0.24%17.02%
Cost of Goods Sold+462K550K701K1.01M719K640K671K686K635K6.19M
COGS % of Revenue0.26%0.28%0.26%0.3%0.46%0.39%0.19%0.25%0.31%0.17%
Gross Profit+1.28M1.44M2.01M2.4M861K1.01M2.88M2.03M1.43M31.02M
Gross Margin %0.74%0.72%0.74%0.7%0.54%0.61%0.81%0.75%0.69%0.83%
Gross Profit Growth %0.65%0.12%0.4%0.19%-0.64%0.17%1.87%-0.3%-0.3%20.69%
Operating Expenses+16.5M17.88M20.18M29.47M20.77M22.31M27.41M35.89M39.61M43.43M
OpEx % of Revenue9.44%8.98%7.43%8.65%13.14%13.55%7.71%13.2%19.18%1.17%
Selling, General & Admin10.01M9.43M9.68M9.82M11.28M11.11M13.64M17.3M22.11M29.55M
SG&A % of Revenue5.73%4.74%3.57%2.88%7.14%6.75%3.84%6.36%10.71%0.79%
Research & Development6.49M8.45M10.49M19.65M9.49M11.2M13.78M18.58M17.5M13.87M
R&D % of Revenue3.71%4.24%3.87%5.77%6.01%6.8%3.88%6.83%8.48%0.37%
Other Operating Expenses-67K0-41K51K000000
Operating Income+-15.21M-16.44M-18.16M-27.07M-19.91M-21.3M-24.53M-33.85M-38.18M-12.41M
Operating Margin %-8.71%-8.25%-6.69%-7.95%-12.6%-12.94%-6.9%-12.45%-18.49%-0.33%
Operating Income Growth %0.21%-0.08%-0.1%-0.49%0.26%-0.07%-0.15%-0.38%-0.13%0.67%
EBITDA+-14.59M-16.14M-17.86M-26.63M-19.66M-21.14M-24.39M-33.72M-37.78M-12.18M
EBITDA Margin %-8.35%-8.1%-6.58%-7.82%-12.44%-12.84%-6.86%-12.4%-18.3%-0.33%
EBITDA Growth %0.2%-0.11%-0.11%-0.49%0.26%-0.08%-0.15%-0.38%-0.12%0.68%
D&A (Non-Cash Add-back)617K305K310K444K249K167K146K132K399K229K
EBIT-14.7M-3.64M-23.41M-11.26M-4.13M-23.98M-24.46M-33.82M-38.18M-12.41M
Net Interest Income+-67K-14.33M-21.7M-7.96M-4.75M-175K-1.19M-2.69M-1.44M0
Interest Income0000000000
Interest Expense67K14.33M21.7M7.96M4.75M175K1.19M2.69M1.44M0
Other Income/Expense506K-1.53M-26.95M7.85M11.03M-2.85M-1.12M-2.65M-9.5M-13.98M
Pretax Income+-14.7M-17.97M-45.12M-19.22M-8.88M-24.16M-25.65M-36.51M-47.68M-26.39M
Pretax Margin %-8.42%-9.02%-16.62%-5.64%-5.62%-14.68%-7.21%-13.43%-23.09%-0.71%
Income Tax+0000000000
Effective Tax Rate %1%1%1%1%1%1%1%1%1%1%
Net Income+-14.7M-17.97M-45.12M-19.22M-8.88M-24.16M-25.65M-36.51M-47.68M-26.39M
Net Margin %-8.42%-9.02%-16.62%-5.64%-5.62%-14.68%-7.21%-13.43%-23.09%-0.71%
Net Income Growth %0.15%-0.22%-1.51%0.57%0.54%-1.72%-0.06%-0.42%-0.31%0.45%
Net Income (Continuing)-14.7M-17.97M-45.12M-19.22M-8.88M-24.16M-25.65M-36.51M-47.68M-26.39M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-999999.00-999999.00-999999.00-503.85-342.82-8.35-3.59-4.12-2.94-0.93
EPS Growth %0.51%0.27%1%1%0.32%0.98%0.57%-0.15%0.29%0.68%
EPS (Basic)-999999.00-999999.00-999999.00-503.85-342.82-8.35-3.59-4.12-2.94-0.93
Diluted Shares Outstanding002038.15K25.9K2.9M7.15M8.86M16.23M28.51M
Basic Shares Outstanding002038.15K25.9K2.9M7.15M8.86M16.23M28.51M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+14.6M34.16M7.59M5.92M12.62M32.34M31.15M16.16M37.16M73.76M
Cash & Short-Term Investments12.61M4.41M4M2.52M10M28.57M22.8M7.67M32.45M53.23M
Cash Only12.61M4.41M4M2.52M10M28.57M22.8M7.67M12.65M32.41M
Short-Term Investments0000000019.81M20.82M
Accounts Receivable277K403K317K1.16M21K57K44K366K483K11.06M
Days Sales Outstanding57.8773.8442.62124.74.8512.644.5249.1385.37108.5
Inventory757K660K1.25M858K654K855K1.41M2M3.32M6.93M
Days Inventory Outstanding598.06438649.81310.38332487.62768.081.06K1.91K408.94
Other Current Assets960K28.04M1.47M1.19M626K509K4.36M4.25M387K1.39M
Total Non-Current Assets+1.13M1.08M1.3M925K1.59M2.3M1.97M1.71M1.46M2.83M
Property, Plant & Equipment1.13M1.08M1.3M925K1.59M2.3M1.97M1.71M1.46M2.83M
Fixed Asset Turnover1.54x1.84x2.09x3.68x0.99x0.72x1.80x1.59x1.42x13.15x
Goodwill0000000000
Intangible Assets0000000000
Long-Term Investments0000000000
Other Non-Current Assets0000000000
Total Assets+15.73M35.24M8.89M6.84M14.21M34.63M33.12M17.86M38.61M76.59M
Asset Turnover0.11x0.06x0.31x0.50x0.11x0.05x0.11x0.15x0.05x0.49x
Asset Growth %-0.34%1.24%-0.75%-0.23%1.08%1.44%-0.04%-0.46%1.16%0.98%
Total Current Liabilities+6.31M36.09M7.81M17.75M15.99M10.04M5.95M14.73M16.45M6.14M
Accounts Payable284K594K3.85M7.71M4.53M1.77M638K2.02M1.01M961K
Days Payables Outstanding224.37394.22K2.79K2.3K1.01K347.051.07K581.756.68
Short-Term Debt013.34M02.04M02M621K7.85M10.15M0
Deferred Revenue (Current)030K01000K482K525K170K000
Other Current Liabilities5.34M21.23M2.84M6.21M9.39M4.3M2.41M1.04M1.93M3.71M
Current Ratio2.31x0.95x0.97x0.33x0.79x3.22x5.23x1.10x2.26x12.01x
Quick Ratio2.19x0.93x0.81x0.29x0.75x3.14x4.99x0.96x2.06x10.88x
Cash Conversion Cycle431.56117.64-1.31K-2.36K-1.96K-511.48425.5538.491.41K460.76
Total Non-Current Liabilities+820K634K395K4.03M4.58M2.52M15.22M8.99M6.39M1.7M
Long-Term Debt00002M015.01M7.84M00
Capital Lease Obligations0000197K450K207K00933K
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities820K604K395K628K0001.14M6.39M766K
Total Liabilities7.13M36.73M8.21M21.78M20.57M12.56M21.17M23.72M22.84M7.84M
Total Debt+013.34M02.04M2.86M2.94M16.25M15.87M10.19M1.04M
Net Debt-12.61M8.93M-4M-478K-7.14M-25.63M-6.55M8.2M-2.46M-31.37M
Debt / Equity-----0.13x1.36x-0.65x0.02x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage-227.01x-1.15x-0.84x-3.40x-4.19x-121.73x-20.68x-12.61x-26.53x-
Total Equity+8.6M-1.49M678K-14.94M-6.36M22.08M11.95M-5.86M15.78M68.75M
Equity Growth %-0.53%-1.17%1.46%-23.03%0.57%4.47%-0.46%-1.49%3.69%3.36%
Book Value per Share0.40-0.3633772.94-391.59-245.447.621.67-0.660.972.41
Total Shareholders' Equity8.6M-1.49M678K-14.94M-6.36M22.08M11.95M-5.86M15.78M68.75M
Common Stock223K41K1.14M103K1K60K79K100K228K331K
Retained Earnings-261.22M-279.19M-324.83M-344.05M-371.17M-395.33M-420.98M-457.48M-505.16M-531.55M
Treasury Stock-51K-51K-51K0000000
Accumulated OCI-8K-41K42K50K28K-104K18K-83K135K82K
Minority Interest0000000000

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-16.42M-14.21M-15.4M-14.73M-23.69M-22.87M-22.6M-24.95M-31.25M-18.68M
Operating CF Margin %-9.4%-7.14%-5.67%-4.32%-14.99%-13.89%-6.36%-9.18%-15.13%-0.5%
Operating CF Growth %-0.06%0.13%-0.08%0.04%-0.61%0.03%0.01%-0.1%-0.25%0.4%
Net Income-14.7M-17.97M-45.12M-19.22M-8.88M-24.16M-25.65M-36.51M-47.68M-26.39M
Depreciation & Amortization617K305K310K444K249K192K146K132K128K229K
Stock-Based Compensation657K427K129K58K277K3.91M7.83M7.94M8.15M9.77M
Deferred Taxes15K1K5.23M-15.76M02.83M0000
Other Non-Cash Items-565K1.49M21.54M7.97M-9.77M159K831K1.37M9.05M13.23M
Working Capital Changes-2.44M1.54M2.51M11.77M-5.56M-5.81M-5.76M2.11M-906K-15.52M
Change in Receivables-52K-138K108K-293K497K-36K13K-322K125K-10.65M
Change in Inventory-420K95K-543K385K204K-201K-557K-587K-1.32M-3.61M
Change in Payables-1.76M1.51M3.18M8.18M-4.79M-5.31M-1.14M1.8M-199K479K
Cash from Investing+10K-1.34M-524K-76K-24K-782K-143K-209K-19.71M-981K
Capital Expenditures-170K-258K-524K-76K-24K-782K-143K-209K-58K-559K
CapEx % of Revenue0.1%0.13%0.19%0.02%0.02%0.48%0.04%0.08%0.03%0.02%
Acquisitions----------
Investments----------
Other Investing180K-1.09M00000000
Cash from Financing+8.65M7.41M15.45M13.24M30.3M42.35M20.82M10.14M51.78M39.41M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid00-527K0000000
Share Repurchases----------
Other Financing0-26.2M2.85M12.44M02.62M2.46M035.01M43M
Net Change in Cash----------
Free Cash Flow+-16.59M-14.47M-15.92M-14.81M-23.71M-23.65M-22.75M-25.16M-31.31M-19.24M
FCF Margin %-9.5%-7.26%-5.86%-4.35%-15.01%-14.37%-6.4%-9.25%-15.16%-0.52%
FCF Growth %-0.06%0.13%-0.1%0.07%-0.6%0%0.04%-0.11%-0.24%0.39%
FCF per Share-0.76-3.52-793116.15-388.15-915.56-8.16-3.18-2.84-1.93-0.67
FCF Conversion (FCF/Net Income)1.12x0.79x0.34x0.77x2.67x0.95x0.88x0.68x0.66x0.71x
Interest Paid0000000000
Taxes Paid0000000000

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-109.95%-505.44%-6654.42%---307.31%-150.74%-1198.36%-961.44%-62.44%
Return on Invested Capital (ROIC)--717.28%-660.87%----1985.78%-655.3%-365.68%-36.72%
Gross Margin73.55%72.39%74.18%70.38%54.49%61.12%81.13%74.77%69.25%83.37%
Net Margin-841.67%-902.16%-1661.77%-564.19%-561.96%-1467.56%-721.49%-1342.7%-2308.86%-70.92%
Debt / Equity-----0.13x1.36x-0.65x0.02x
Interest Coverage-227.01x-1.15x-0.84x-3.40x-4.19x-121.73x-20.68x-12.61x-26.53x-
FCF Conversion1.12x0.79x0.34x0.77x2.67x0.95x0.88x0.68x0.66x0.71x
Revenue Growth63.42%14.02%36.3%25.49%-53.62%4.18%115.98%-23.52%-24.05%1701.69%

Revenue by Segment

201820192020202120222023
Product3.38M1.1M1.16M1.3M2.55M2.06M
Product Growth--67.41%5.00%12.46%96.00%-18.96%
Product and Service, Other---2.25M171K-
Product and Service, Other Growth-----92.42%-
Product And Service Other29K479K490K---
Product And Service Other Growth-1551.72%2.30%---

Frequently Asked Questions

Growth & Financials

Delcath Systems, Inc. (DCTH) reported $79.6M in revenue for fiscal year 2024.

Delcath Systems, Inc. (DCTH) grew revenue by 1701.7% over the past year. This is strong growth.

Yes, Delcath Systems, Inc. (DCTH) is profitable, generating $1.2M in net income for fiscal year 2024 (-70.9% net margin).

Dividend & Returns

Delcath Systems, Inc. (DCTH) has a return on equity (ROE) of -62.4%. Negative ROE indicates the company is unprofitable.

Delcath Systems, Inc. (DCTH) generated $12.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.